SGLT2 Inhibitors Suppress Alpha-Adrenergic Tone and Morning Elevation of Plasma Glucose Levels
| Autor: | Keishi Yamauchi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Adrenergic receptor Chemistry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Adrenergic 030204 cardiovascular system & hematology Normetanephrine Norepinephrine (medication) 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Ipragliflozin Epinephrine Internal medicine Internal Medicine medicine 030212 general & internal medicine SGLT2 Inhibitor medicine.drug |
| Zdroj: | Diabetes. 67 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | Previously, we reported that morning plasma glucose (PG) elevation before wake-up (W1) and after wake-up (W2), occur through different mechanisms in patients with type 2 diabetes. W1 was related to insulin deficiency as already-known reports. W2 could be explained by heightened ambient alpha-adrenergic tone, within the normal range since urinary normetanephrine was strongly related to W2. Urinary normetanephrine are reflected production levels of norepinephrine. Although epinephrine activates both of α and β adrenergic receptors, norepinephrine only stimulates α adrenergic receptor. In the study, we estimate the effect of SGLT2 inhibitors on urinary metanephrines, other antagonistic hormones and W2. Ipragliflozin (50mg) or dapagliflozin (5mg) administered 8 diabetic patients with W2 for 3 month. Those with insulin therapy or overtly elevated fasting PG (>11 mmol/L) were excluded. SGLT2 inhibitors suppressed δPG(8 am PG minus 6 am PG) (2.7±1.1 mmol/L to 1.9±0.9 mmol/L, p0.05) and other antagonistic hormones. Adrenergic tone-induced alterations of glucose metabolism may be mediated via regulation of SGLT2 inhibitor. Disclosure K. Yamauchi: None. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|